更新于 今天

生物學(xué)高級(jí)經(jīng)理

3-4萬·14薪
  • 上海閔行區(qū)
  • 5-10年
  • 博士
  • 全職
  • 招1人

職位描述

生物藥抗體藥分子生物學(xué)技術(shù)

Job Description:

Qualifications

1. Lead/manage a team of biologists supporting in vitro screening of biologics; Establish robust and reproducible in vitro screening assays, technical platforms to evaluate biologics.

2. Identify and validate novel drug targets for unmet medical needs in major disease areas, including oncology/immunology/metabolic diseases /CVD or a relevant major disease field, with sound scientific rationale, and coming up with proposals for promising drug targets that drive the company’s R&D pipeline.

3. As a project leader, lead drug discovery programs, responsible for
setting up strategic direction and leading the program all the way to reach the milestone of approval of preclinical candidates. Coordinating various functions with different groups to drive the programs forward. Assisting in out-licensing/collaboration when needed.

Requirements:

MD or PhD/Post Doc education with in-depth knowledge in oncology/immunology/metabolic diseases/ CVD or a relevant field;

Strong abilities in critically analyzing research papers, Excellent leadership and teamwork skills;

Proficient in written English and presentation skills;

Good track record of publications. Relevant drug discovery experience from a reputable pharm/biotech company is needed;

a strong desire for success in novel drug discovery.


工作地點(diǎn)

上海市閔行經(jīng)濟(jì)開發(fā)區(qū)文井路279號(hào)

職位發(fā)布者

洪女士/人力資源主管

剛剛活躍
立即溝通
公司Logo上海恒瑞醫(yī)藥有限公司
上海恒瑞醫(yī)藥有限公司系江蘇恒瑞醫(yī)藥股份有限公司的全資子公司,創(chuàng)立于2001年,占地4.4萬平方米,擁有國內(nèi)領(lǐng)先的科研實(shí)驗(yàn)基地和高水準(zhǔn)的GMP生產(chǎn)車間。上海恒瑞作為恒瑞醫(yī)藥最大的研發(fā)中心,主要致力于創(chuàng)新藥物的早期研發(fā),除傳統(tǒng)優(yōu)勢的腫瘤領(lǐng)域,還前瞻性地廣泛布局自身免疫疾病、疼痛管理、心血管疾病、代謝性疾病等多個(gè)治療領(lǐng)域。公司建立了一批具有自主知識(shí)產(chǎn)權(quán)、國際一流的新技術(shù)平臺(tái),如ADC、PROTAC、雙抗及AI藥物設(shè)計(jì)平臺(tái)等,為創(chuàng)新研發(fā)提供強(qiáng)大基礎(chǔ)保障。公司研發(fā)人員600余人,占比高達(dá)46%。恒瑞醫(yī)藥已上市的13個(gè)1類新藥中,馬來酸吡咯替尼、卡瑞利珠單抗、瑞維魯胺等9款新藥的早期開發(fā)均在上海恒瑞完成,適應(yīng)癥覆蓋腫瘤及其輔助治療、糖尿病、血液疾病等,具有高臨床價(jià)值,已陸續(xù)進(jìn)入國家醫(yī)保目錄,大幅減輕患者經(jīng)濟(jì)負(fù)擔(dān),提高用藥可及性。近年來,上海恒瑞先后承擔(dān)國家重大專項(xiàng)課題19項(xiàng),推進(jìn)60余個(gè)創(chuàng)新藥品種進(jìn)入臨床開發(fā),10余個(gè)創(chuàng)新藥在美國、澳大利亞等地開展臨床試驗(yàn)。公司累計(jì)申請(qǐng)國內(nèi)發(fā)明專利400余項(xiàng),擁有國內(nèi)有效授權(quán)發(fā)明專利250余件,歐美日等國外授權(quán)專利350余件。
公司主頁